Evidence for Enhanced Intestinal Absorption of Digoxin by P-Glycoprotein Inhibitors

被引:10
|
作者
Valizadeh, Hadi [2 ]
Mehtari, Maryam [3 ]
Zakeri-Milani, Parvin [1 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Drug Appl Res Ctr, Tabriz, Iran
关键词
Digoxin; Macrolides; Efflux; Intestinal permeability; P-glycoprotein; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; MACROLIDE ANTIBIOTICS; RAT; PERMEABILITY; TRANSPORTER; EXSORPTION;
D O I
10.4314/tjpr.v11i6.10
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of macrolides as P-glycoprotein inhibitors on the level of intestinal absorption of digoxin. Methods: Jejunal segments of anaesthetized rats were cannulated and perfused by digoxin in phosphate buffered saline (PBS) at 37 degrees C in the presence or absence of macrolides (erythromycin and clarithromycin). Samples were obtained from outlet tubing at different time points and digoxin concentration assayed. The effective permeability of the drug was calculated after analyzing the samples using reverse-phase HPLC method. Results: Digoxin effective permeability was in the range of 0.24 +/- 0.02 x 10(-4) to 0.32 +/- 0.06 x 10(-4) cm/sec for the control group. The macrolides significantly (p < 0.05) increased intestinal transport of digoxin, with digoxin in the presence of 150 mu M of each macrolide in the range 0.42 +/- 0.08 x 10(-4) to 0.52 +/- 0.07 x 10(-4) cm/sec. However, no significant difference (p > 0.05) was observed between the effects of the two macrolides. Conclusion: The probable explanation for digoxin-macrolide interaction is inhibition of intestinal P-glycoprotein-mediated efflux of digoxin which leads to increased digoxin intestinal absorption.
引用
收藏
页码:939 / 945
页数:7
相关论文
共 50 条
  • [41] Interaction of mouse intestinal P-glycoprotein with oral antidiabetic drugs and its inhibitors
    Kaisi, Harman
    Grewal, Ravneet K.
    INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 2015, 53 (09) : 611 - 616
  • [42] Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl
    Kharasch, ED
    Hoffer, C
    Altuntas, TG
    Whittington, D
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (03): : 224 - 233
  • [43] Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats
    Mori, N.
    Iwamoto, H.
    Yokooji, T.
    Murakami, T.
    PHARMAZIE, 2012, 67 (05): : 384 - 388
  • [44] In vitro-in vivo correlation in p-glycoprotein mediated transport in intestinal absorption
    del Amo, Eva M.
    Heikkinen, Aki T.
    Monkkonen, Jukka
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 36 (2-3) : 200 - 211
  • [45] The involvement of P-glycoprotein in berberine absorption
    Pan, GY
    Wang, GJ
    Liu, XD
    Fawcett, JP
    Xie, YY
    PHARMACOLOGY & TOXICOLOGY, 2002, 91 (04): : 193 - 197
  • [46] Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats
    He, Huijuan
    Shen, Qi
    Li, Jian
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (07) : 1161 - 1170
  • [47] Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats
    Huijuan He
    Qi Shen
    Jian Li
    Archives of Pharmacal Research, 2011, 34 : 1161 - 1170
  • [48] Impact of P-glycoprotein on clopidogrel absorption
    Taubert, Dirk
    von Beckerath, Nicolas
    Grimberg, Gundula
    Lazar, Andreas
    Jung, Norma
    Goeser, Tobias
    Kastrati, Adnan
    Schoemig, Albert
    Schoemig, Edgar
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (05) : 486 - 501
  • [49] Saquinavir absorption: Role of P-glycoprotein
    Back, D
    Eagling, V
    Profit, L
    AIDS, 1998, 12 : S31 - S31
  • [50] Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-gp) in humans.
    Chan, L
    Humma, LM
    Schriever, CA
    Fahsingbauer, LA
    Dominguez, CP
    Baum, CL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P95 - P95